Precision Genomic Testing Market - Databook 2025 to 2034

The global precision genomic testing market size was calculated at USD 15,510 million in 2024 and is predicted to attain around USD 62,200 million by 2034, expanding at a CAGR of 14.9% from 2025 to 2034.

Precision Genomic Testing Market Report Highlights

• North America held the largest share of the market in 2024.
• Asia Pacific is projected to host the fastest-growing market in the coming years.
• By products & services, the consumables segment enjoyed a prominent position in the precision genomic testing market in 2024.
• By products & services, the services segment will gain a significant share of the market over the studied period of 2025 to 2034.
• By application, the oncology segment enjoyed a prominent portion of the market in 2024.
• By application, the neurological disorders segment is predicted to witness significant growth in the market over the forecast period.
• By technology, the next-generation sequencing segment captured a significant portion of the market in 2024.
• By technology, the microarray technology segment is projected to expand rapidly in the precision genomic testing market in the coming years.
• By end-use, the hospitals and clinics companies segment maintained a leading position in the market in 2024.
• By end-use, the diagnostic laboratories segment is anticipated to grow with the highest CAGR in the market during the studied years.

Industry Valuation and Growth Rate Projection

The precision genomic testing market refers to the production, distribution, and application of precision genomic testing, which looks at the genetics, environment, and lifestyle of a person to select the treatment that could work best for them. Precision genomic testing looks at the genetics of tumors as well as normal DNA. The test aims to find changes in your genes that can affect your health. It starts by taking a DNA sample, generally tissue, saliva, or blood sample. The DNA is analyzed by computer programs and ‘written out’ as a letter code, which is unique to each person. Genomics has many benefits in precision medicine.

Next-generation sequencing (NGS) can sequence multiple genes at once, identify disease-associated variants to help match patients to therapies or assess disease risk, and help target therapies and reduce overall care costs. The expansion of precision medicine is based on using many sources from genomics, biological data, transcriptomics, and proteomics crucial for prediction, to be more precise and accurate in diagnoses, definitions, and treatments of disease subtypes. Genomic testing is used to help guide prevention or treatment plans that will enhance healthcare outcomes and reduce adverse events.

AI-based bioinformatics driving the growth of the precision genomic testing market. By integrating AI with bioinformatics, researchers can develop predictive models that are not only more accurate but also more robust and reliable. Additionally, the synergy between AI and bioinformatics allows the discovery of new insights and associations in biological systems. AI contributes to predicting and optimizing genome editing methods like CRISPR-Cas9. ML algorithms can analyze large-scale genetic sequence datasets, which can then be used to steer the

development of more accurate and effective genome editing technologies by predicting probable off-target consequences. Scientists can use AI models to understand and analyze genetic sequences or predict sequence properties and design new sequences. This moves biology from a descriptive to a more predictive and ultimately engineering realm, advancing the domains of medicine, biotechnology, synthetic biology, and beyond. The AI benefits include better innovation, enhanced efficiency, and task automation. AI-based bioinformatics benefits include the advancement of medical discovery and development of treatments, disease monitoring and prevention, and enhancing the overall effectiveness and precision of clinical medicine.

CRISPR gene editing driving the growth of the precision genomic testing market. CRISPR gene editing has gifted us everything from new cancer therapies to the ability to create animals resistant to specific diseases. CRISPR gene editing allows scientists to quickly create cell and animal models, which researchers can use to accelerate research into diseases such as cancer and mental illness. Additionally, CRISPR is now being developed as a rapid diagnostic tool.

Compared with the conventional approaches for the improvement of the expression of specific genes of interest, the CRISPR/Cas-9-based system has emerged as a promising technology for genome regulation, allowing convenience, specificity, robustness, and scalability for endogenous gene activation. Due to its efficiency and affinity, CRISPR has been considered to be a revolutionary invention in the field of genetic editing and molecular biology. Compared with other genetic editing technologies, CRISPR has an irreplaceable advantage, which is its accessibility.